Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01830881 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Oral Midazolam in First-trimester Surgical Abortions
A Phase 4 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 4
- Development phase
- 124
- Enrollment target
NCT01830881: Completed Phase 4 study, sponsored by Oregon Health and Science University.
NCT01830881 is a Phase 4 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 124 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01830881, a Phase 4 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 124 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the level of pain, anxiety and side effects that women experience with a surgical abortion and the effect that the anti-anxiety medication, midazolam, might have when used along with ibuprofen and a paracervical block (PCB) instead of the standard pain treatment of only ibuprofen and a PCB.
Primary Outcome
Subjects will be asked to rate anxiety and pain at the time of uterine aspiration by marking along a 100 mm Visual Analog Scale, with 0mm being No Pain/Anxiety and 100mm being Worst Imaginable Pain/Anxiety
Interventions
- DRUG Ibuprofen
- DRUG Midazolam
- DRUG Lidocaine
- OTHER Placebo-Cherry syrup
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2013-04 |
| Est. Completion | 2014-01 |
| Phase | Phase 4 |
What the finished NCT01830881 record still lists
NCT01830881 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 4 interventions - of which Ibuprofen is the first listed.
NCT01830881 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01830881 about?
NCT01830881 is a clinical study titled "Evaluation of Oral Midazolam in First-trimester Surgical Abortions". The purpose of this study is to determine the level of pain, anxiety and side effects that women experience with a surgical abortion and the effect that the anti-anxiety medication, midazolam, might have when used along with ibuprofen and a paracervical block (PCB) instead of the standard pain treat...
What is the current status of trial NCT01830881?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 124 participants. The study started on 2013-04. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01830881?
The interventions under investigation include: Ibuprofen (DRUG), Midazolam (DRUG), Lidocaine (DRUG), Placebo-Cherry syrup (OTHER).
Who is sponsoring clinical trial NCT01830881?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01830881's enrollment target sits among peer trials
124 656th of 2000 higher than 1,339 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia